Novo Nordisk Files for US FDA Approval of Oral Semaglutide for Blood Sugar Control and Cardiovascular Risk Reduction in Adults with Type 2 Diabetes 27/03/2019 Medications PLAINSBORO, N.J., March 20, 2019 /PRNewswire/ — Novo Nordisk today Read more